Insights Center

Thought leadership, news, events — you will find them all here, right at your fingertips. We’ve consolidated the firm’s most popular content in one, easy to search location. Enter a key word or phrase to find pertinent blog posts, articles, press releases, and upcoming events.

Featured

Mintz Direct

On our new Mintz Direct page, Mintz thought leaders across industries and practice areas offer timely insights on developments that impact our clients and communities. Visit the Mintz Direct page to hear what our experienced attorneys and professionals are saying about what’s happening now.

Mintz Viewpoints

Use quotation marks to search for an exact phrase (e.g. “class action”)

Published

Showing 6617 - 6624 of 12007 results

Federal Trade Commission Announces Workshop on Competition in the Prescription Drug Market

October 9, 2017| Blog| Viewpoint

InsureTech Connect 2017 Panel Discussion: Maximizing Profits via Products and Alternative Business Model Innovation

October 9, 2017| Article| Viewpoint

3 Billion Compromised Yahoo Accounts May Yield Largest Plaintiff Class Ever

October 6, 2017| Blog| Viewpoint

Canada Institutes Certificates of Supplementary Protection for Approved Drug Products

October 6, 2017| Blog| Viewpoint

ALJ Shaw: ITC is a Viable Forum for Enforcement of SEPs

October 6, 2017| Blog| Viewpoint

CPSC Round-Up: Buerkle Confirmation Hearing, Landmark Civil Penalty Ruling, and Partisan Action on Flame Retardants

October 6, 2017| Blog| Viewpoint

Reminder: New York City Ban on Salary History Inquiries Takes Effect October 31st

October 5, 2017| Blog| Viewpoint

AQUA PRODUCTS: The Federal Circuit Shifts The Burden of Proof On Amending Claims During An IPR From The Patent Owner To The Petitioner

October 5, 2017| Blog| Viewpoint

News & Press Releases

Mintz Advises ArriVent BioPharma on $75 Million Underwritten Public Offering

July 08, 2025

Mintz advised ArriVent BioPharma, Inc., a clinical-stage biopharmaceutical company dedicated to the identification, development, and commercialization of differentiated medicines to address the unmet medical needs of patients with cancers, on a $75 million underwritten public offering of 2,482,692 shares of its common stock and pre-funded warrants to purchase up to 1,363,469 shares of its common stock. The common stock is listed on The Nasdaq Global Market under the symbol “AVBP.“

Mintz Advises S2G Investments on $40M Series B Financing of Sojo Industries

July 07, 2025

Mintz represented S2G Investments, a multi-stage investment firm focused on venture and growth-stage businesses across food & agriculture, oceans and energy, in its $40 million Series B financing of Sojo Industries, an industrial automation company that utilizes robotics, mobility, and software to deliver packaging and assembly solutions to the food and beverage industry.

Mintz Advises Syntis Bio on $33 Million Series A Financing

July 02, 2025

Mintz advised Syntis Bio, a clinical-stage biopharmaceutical company revolutionizing oral therapies for obesity, diabetes, and rare diseases, on a $33 million oversubscribed Series A financing.

View all News and Press Releases